-
1دورية أكاديمية
المؤلفون: Wolf, J, Kaiser, T, Pehnke, S, Nickel, O, Lubbert, C, Kalbitz, S, Arnold, B, Ermisch, J, Berger, L, Schroth, S, Isermann, B, Borte, S, Biemann, R
المصدر: Clinica chimica acta. 511:352-359
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
المؤلفون: Wendt, R, Nagel, S, Nickel, O, Wolf, J, Kalbitz, S, Kaiser, T, Borte, S, Lubbert, C
المصدر: Infection control and hospital epidemiology. 41(10):1209-1211
مصطلحات موضوعية: Medicin och hälsovetenskap
-
3دورية أكاديمية
المؤلفون: Nickel, O, Rockstroh, A, Wolf, J, Landgraf, S, Kalbitz, S, Kellner, N, Borte, M, Pietsch, C, Fertey, J, Lubbert, C, Ulbert, S, Borte, S
المصدر: PloS one. 17(10):e0263861
مصطلحات موضوعية: Medicin och hälsovetenskap
-
4دورية أكاديمية
المؤلفون: Marx, K, Kalbitz, S, Kellner, N, Fedders, M, Lübbert, C
المصدر: GMS Infectious Diseases; VOL: 11; DOC03 /20230928/
مصطلحات موضوعية: SARS-CoV-2, COVID-19, treatment, antiviral agents, monoclonal antibodies, variants of concern, pandemic waves, ddc: 610
العلاقة: Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2023 Feb;95(2):e28441. DOI:10.1002/jmv.28441; Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. Rev Med Virol. 2022 Nov;32(6):e2402. DOI:10.1002/rmv.2402; Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Müller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schönenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023 May;11(5):453-64. DOI:10.1016/S2213-2600(22)00528-8; Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. Beschreibung des bisherigen Ausbruchsgeschehens mit dem neuartigen Coronavirus SARS-CoV 2 in Deutschland (Stand: 12. Februar 2020). Epid Bull. 2020;7:3-4.; Bundesministerium für Gesundheit (BMG). Bekanntmachung der Allgemeinverfügung zum Bezug und zur Anwendung monoklonaler Antikörper und zum Bezug und zur Abgabe antiviraler, oral einzunehmender Arzneimittel gegen COVID-19 vom 4. Januar 2022. 2022 [last accessed 2023 Mar 28]. Available from: https://www.bundesanzeiger.de/pub/publication/yKdCDkGe0Cb1Lj1A2J2/content/yKdCDkGe0Cb1Lj1A2J2/BAnz%20AT%2014.01.2022%20B2.pdf?inlineTest; Bundesministerium für Gesundheit (BMG). Verordnung zur Sicherstellung der Versorgung der Bevölkerung mit Produkten des medizinischen Bedarfs bei der durch das Coronavirus SARS-CoV-2 verursachten Epidemie (Medizinischer Bedarf Versorgungssicherstellungsverordnung - MedBVSV). [last accessed 2023 Mar 28]. Available from: https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/guv-19-lp/medbvsv.htmlTest; Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, Kovalchuk E, Gonzalez A, Brown ML, Williams-Diaz A, Gao W, Strizki JM, Grobler J, Du J, Assaid CA, Paschke A, Butterton JF, Johnson MG, de Anda C; Pharm.D., for the MOVe-OUT Study Group. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. NEJM Evid 2022;1(2). DOI:10.1056/EVIDoa2100043; Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Roche N. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021 Apr 15;57(4):2100048. DOI:10.1183/13993003.00048-2021; Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN); Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI); Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP); Deutsche Gesellschaft für Infektiologie (DGI), et al. S3-Leitlinie Empfehlungen zur stationären Therapie von Patienten mit COVID-19. AWMF-Registernummer 113-001. Update 2023. Langfassung. AWMF; 2023. Available from: https://register.awmf.org/de/leitlinien/detail/113-001LGTest; European Medicines Agency (EMA). Xevudy: Summary of Product characteristics. [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdfTest; European Medicines Agency (EMA). Veklury: Summary of Product Characteristics. [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/veklury-epar-product-information_en.pdfTest; European Medicines Agency (EMA). Paxlovid: Summary of Product Characteristics. [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdfTest; European Medicines Agency (EMA). EMA recommends conditional marketing authorisation for Paxlovid. 2022 Jan 27 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/news/covid-19-ema-recommends-conditional-marketing-authorisation-paxlovidTest; European Medicines Agency (EMA). CHMP post-authorisation summary of positive opinion for Veklury (II-12). 2020 Dec 10 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veklury-ii-12_en.pdfTest; European Medicines Agency (EMA). EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19. 2021 Mar 11 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/news/ema-starts-rolling-review-eli-lilly-antibodies-bamlanivimab-etesevimab-covid-19Test; European Medicines Agency (EMA). CHMP: Summary of Opinion for Evusheld. 2022 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evusheldTest; European Medicines Agency (EMA). EMA issues advice on use of REGN-COV2 antibody combination (casirivimab/imdevimab). 2021 Feb 26 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimabTest; European Medicines Agency (EMA). Refusal of the marketing authorisation for Lagevrio (molnupiravir). 2023 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdfTest; European Medicines Agency (EMA). Evusheld: Summary of Product Characteristics. 2022 [last accessed 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evusheldTest; Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C, Peppercorn A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-50. DOI:10.1056/NEJMoa2107934; Malin JJ, Spinner CD, Janssens U, Welte T, Weber-Carstens S, Schälte G, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe KF, Hoffmann F, Böttiger BW, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Fichtner F, Laudi S, Stegemann M, Skoetz N, Nothacker M, Marx G, Karagiannidis C, Kluge S. Key summary of German national treatment guidance for hospitalized COVID-19 patients: Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework. Infection. 2022 Feb;50(1):93-106. DOI:10.1007/s15010-021-01645-2; Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, Brooks D, Garbes P, Jimenez J, Koh GCKW, Padilla KW, Streicher K, Viani RM, Alagappan V, Pangalos MN, Esser MT; TACKLE study group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022 Oct;10(10):985-96. DOI:10.1016/S2213-2600(22)00180-1; Razonable RR, Tulledge-Scheitel SM, Hanson SN, Arndt RF, Speicher LL, Seville TA, Larsen JJ, Ganesh R, O'Horo JC. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch. Open Forum Infect Dis. 2022 Oct 6;9(10):ofac411. DOI:10.1093/ofid/ofac411; RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Feb 12;399(10325):665-76. DOI:10.1016/S0140-6736(22)00163-5; Regeneron Pharmaceuticals. REGEN-COV(TM) (casirivimab and imdevimab) phase 3 RECOVERY trial meets primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2. 2021 Jun 16 [last accessed 2023 Mar 28]. Available from: https://investor.regeneron.com/news-releases/news-release-details/regen-covtm-casirivimab-and-imdevimab-phase-3-recovery-trialTest/; Robert Koch-Institut (RKI). COVID-19: Fallzahlen in Deutschland und weltweit. [last accessed 2023 28 Mar]. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.htmlTest; Robert Koch-Institut (RKI). Risikobewertung zu COVID-19. [last accessed 2023 Mar 28]. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikobewertung.htmlTest; Robert Koch-Institut (RKI). Übersicht zu besorgniserregenden SARS-CoV-2-Virusvarianten (VOC). [last accessed 2023 Mar 28]. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Virusvariante.htmlTest; Robert Koch-Institut (RKI). Liste der Stern- und Satellitenapotheken (beauftragte Stellen nach $ 2 Absatz 1 MedBVSV). [last accessed 2023 Mar 28]. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Therapie/Stern-Satellitenapotheken.pdfTest; Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger am Robert Koch-Institut (STAKOB). Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19 - Stand 28. April 2021. [last accessed 2023 Mar 28]. Available from: https://www.rki.de/covid-19-therapie-stakobTest; Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger am Robert Koch-Institut (STAKOB). Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19. [last accessed 2023 Mar 28]. Available from: https://www.rki.de/covid-19-therapie-stakobTest; Tolksdorf K, Loenenbach A, Buda S. Dritte Aktualisierung der "Retrospektiven Phaseneinteilung der COVID-19-Pandemie in Deutschland". Epid Bull. 2022;38:3-6.; Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022 Dec;22(12):1681-93. DOI:10.1016/S1473-3099(22)00507-2; World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. [last accessed 2023 Mar 28]. Available from: https://covid19.who.intTest/; World Health Organization (WHO). Therapeutics and COVID-19: living guideline. 2022 [last accessed 2023 Mar 28]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1Test; World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19. 2020 Mar 1 [last accessed 2023 Mar 28]. Available from: https://www.who.int/director-general/speeches/detail/who-director-generalTest-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020; http://dx.doi.org/10.3205/id000083Test; http://nbn-resolving.de/urn:nbn:de:0183-id0000831Test; http://www.egms.de/en/journals/id/2023-11/id000083.shtmlTest
الإتاحة: https://doi.org/10.3205/id000083Test
https://doi.org/10.1002/jmv.28441Test
https://doi.org/10.1002/rmv.2402Test
https://doi.org/10.1016/S2213-2600Test(22)00528-8
https://doi.org/10.1056/EVIDoa2100043Test
https://doi.org/10.1183/13993003.00048-2021Test
https://doi.org/10.1056/NEJMoa2107934Test
https://doi.org/10.1007/s15010-021-01645-2Test
https://doi.org/10.1016/S2213-2600Test(22)00180-1
https://doi.org/10.1093/ofid/ofac411Test -
5دورية أكاديمية
المؤلفون: Wendt, R, Nickel, O, Kalbitz, S, Fertey, J, Ulbert, S, Wolf, J, Lübbert, C, Borte, S
المصدر: GMS Hygiene and Infection Control; VOL: 16; DOC03 /20210119/
مصطلحات موضوعية: SARS-CoV-2, PCR, swabs, pharyngeal lavage, COVID-19, Abstriche, Rachenspülwasser, ddc: 610
العلاقة: Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan;25(3):2000045. DOI:10.2807/1560-7917.ES.2020.25.3.2000045.; Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S, Barati S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L, Zhong XZ, McGeer AJ, Mubareka S; Toronto Invasive Bacterial Diseases Network COVID-19 Investigators. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [Preprint]. medRxiv. 2020. DOI:10.1101/2020.05.01.20081026; Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W, Sungkanuparph S, Phuphuakrat A. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin Microbiol Infect. 2020 May. DOI:10.1016/j.cmi.2020.05.001; Srivatsan S, Han PD, van Raay K, Wolf CR, McCulloch DJ, Kim AE, Brandstetter E, Martin B, Gehring J, Chen W; Seattle Flu Study Investigators, Kosuri S, Konnick EQ, Lockwood CM, Rieder MJ, Nickerson DA, Chu HY, Shendure J, Starita LM. Preliminary support for a "dry swab, extraction free" protocol for SARS-CoV-2 testing via RT-qPCR [Preprint]. bioRxiv. 2020. DOI:10.1101/2020.04.22.056283; Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 05;581(7809):465-9. DOI:10.1038/s41586-020-2196-x; Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs [Preprint]. medRxiv. 2020. DOI:10.1101/2020.04.16.20067835; http://dx.doi.org/10.3205/dgkh000374Test; http://nbn-resolving.de/urn:nbn:de:0183-dgkh0003745Test; http://www.egms.de/en/journals/dgkh/2021-16/dgkh000374.shtmlTest
الإتاحة: https://doi.org/10.3205/dgkh000374Test
https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045Test
https://doi.org/10.1101/2020.05.01.20081026Test
https://doi.org/10.1016/j.cmi.2020.05.001Test
https://doi.org/10.1101/2020.04.22.056283Test
https://doi.org/10.1038/s41586-020-2196-xTest
https://doi.org/10.1101/2020.04.16.20067835Test
http://nbn-resolving.de/urn:nbn:de:0183-dgkh0003745Test
http://www.egms.de/en/journals/dgkh/2021-16/dgkh000374.shtmlTest -
6مؤتمر
المؤلفون: Schmidt-Pokrzywniak, A, Kalbitz, S, Jöckel, KH, Bornfeld, N, Stang, A
المصدر: Mainz//2011; 56. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 6. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi); 20110926-20110929; Mainz; DOC11gmds204 /20110920/
مصطلحات موضوعية: Aderhautmelanom, Prognose, Überlebensraten, ddc: 610
العلاقة: Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834-40.; Egan KM, QuinnJl, Gragoudas ES. Childbearing history associated with improved survival choroidal melanoma. Arch Ophthalmol. 1988;117(7):939-42.; McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13(2):123-32.; Regan S, Judge HE, Gragoudas ES, Egan KM. Iris color as a prognostic factor in ocular melanoma. Arch Ophthalmol. 1999;117(6):811-4.; Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114:2309-15.; http://dx.doi.org/10.3205/11gmds204Test; http://nbn-resolving.de/urn:nbn:de:0183-11gmds2049Test; http://www.egms.de/en/meetings/gmds2011/11gmds204.shtmlTest
الإتاحة: https://doi.org/10.3205/11gmds204Test
http://nbn-resolving.de/urn:nbn:de:0183-11gmds2049Test
http://www.egms.de/en/meetings/gmds2011/11gmds204.shtmlTest -
7دورية أكاديمية
المؤلفون: Müller, E., Kalbitz, S.
المصدر: Journal of Animal Breeding and Genetics ; volume 112, issue 1-6, page 281-292 ; ISSN 0931-2668 1439-0388
-
8دورية أكاديمية
المؤلفون: Wendt, Ralph, Lingitz, Marie-Therese, Laggner, Maria, Mildner, Michael, Traxler, Denise, Graf, Alexandra, Krotka, Pavla, Moser, Bernhard, Hoetzenecker, Konrad, Kalbitz, Sven, Lübbert, Christoph, Beige, Joachim, Ankersmit, Hendrik Jan
مصطلحات موضوعية: COVID-19, HSP27, sST2, ARDS, biomarker, 20S proteasome, info:eu-repo/classification/ddc/570, ddc:570
العلاقة: 1186
-
9دورية أكاديمية
مصطلحات موضوعية: Septic portal vein thrombosis, Pylephlebitis, Leptospirosis, Polymicrobial infection, Colonic diverticulitis, Anticoagulation, Case report, info:eu-repo/classification/ddc/610, ddc:610
-
10دورية أكاديمية
المؤلفون: Günzler, R., Weiser, M., Kalbitz, S.
المصدر: Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms ; volume 62, issue 3, page 350-355 ; ISSN 0168-583X
مصطلحات موضوعية: Instrumentation, Nuclear and High Energy Physics
الإتاحة: https://doi.org/10.1016/0168-583xTest(92)95255-p
https://api.elsevier.com/content/article/PII:0168583X9295255P?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:0168583X9295255P?httpAccept=text/plainTest
النص الكامل